Mostrar el registro sencillo del ítem

dc.contributor.authorDíaz-Sánchez, Estela
dc.contributor.authorLópez-Salas, Alexander
dc.contributor.authorÁlvarez-Contino, José Erik
dc.contributor.authorBarbancho-Fernández, Miguel Ángel 
dc.contributor.authorSánchez-Pérez, José Andrés
dc.contributor.authorBlanco-Reina, Encarnación 
dc.contributor.authorBrito Rodríguez, Ismel
dc.contributor.authorSerrano-Castro, Pedro Jesús 
dc.contributor.authorFuxe, Kjell
dc.contributor.authorBorroto Escuela, Dasiel Óscar
dc.contributor.authorGarcía-Casares, Natalia 
dc.contributor.authorNarváez-Peláez, Manuel 
dc.date.accessioned2023-09-27T09:49:30Z
dc.date.available2023-09-27T09:49:30Z
dc.date.created2023-09-13
dc.date.issued2023
dc.identifier.urihttps://hdl.handle.net/10630/27677
dc.description.abstractThe intricate relationship between hippocampal neurogenesis dysregulation and neurodegenerative diseases such as Alzheimer's, as well as depression, has sparked an urgent call for innovative therapeutic strategies. Our groundbreaking study delves into the interaction of Neuropeptide Y (NPY) and galanin (GAL) agonists, two neuromodulatory systems with a substantial presence in the limbic system, and their potential neurogenic impact on both the dorsal and ventral hippocampus. Through meticulous examination of the subchronic e"ects of NPY Y1 (Y1R) and GAL2 (GALR2) agonists on hippocampal cell proliferation, survival, and neuroprotective factor expression, we reveal a fascinating cascade of cellular responses. These include increased cell proliferation (PCNA), enhanced hippocampal cell survival (BrdU), and induction of neuroprotective factors (BDNF). Our functional assessment showcases the resulting improvements in spatial memory performance in the object-in-place task and antidepressant-like e"ects in the forced swimming test. These outcomes are attributed to the synergistic interaction between Y1R and GALR2 receptors, which promote neuronal survival and neurite outgrowth in hippocampal cells. This pioneering research paves the way for the development of heterobivalent agonist pharmacophores that target Y1R-GALR2 heterocomplexes. By acting on neuronal precursor cells in the dentate gyrus of the dorsal hippocampus, these novel compounds hold immense promise as transformative therapies for cognitive and a"ective impairments in neurodegenerative and depressive diseases.es_ES
dc.description.sponsorshipSupported by the Proy_Excel_2021_0613 (Junta de Andalucía) and Proyecto Puente (B4-2021) (UMA), Spain to MN. Swedish Medical Research Council, Sweden (62X-00715-50-3), to KF, by Stiftelsen Olle Engkvist Byggmästare to KF, and by Hjärnfonden, Sweden (F02018-0286), Hjärnfonden, Sweden (F02019-0296) and EMERGIA2020 (Junta de Andalucía), to DOBE. Universidad de Málaga. Campus de Excelencia Internacional Andalucía Tech.es_ES
dc.language.isoenges_ES
dc.rightsinfo:eu-repo/semantics/embargoedAccesses_ES
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subjectCerebro - Enfermedadeses_ES
dc.subjectNeuronas - Crecimientoes_ES
dc.subject.otherExcitabilidad neuronales_ES
dc.subject.otherGalaninaes_ES
dc.subject.otherNeurogénesises_ES
dc.subject.otherNeuropeptido Yes_ES
dc.titleUnveiling the Synergistic Interplay of Neuropeptides for Novel Therapeutic Approaches in Neurodegenerative and Depressive Disorders.es_ES
dc.typeinfo:eu-repo/semantics/conferenceObjectes_ES
dc.centroFacultad de Medicinaes_ES
dc.relation.eventtitle11th IBRO World Congresses_ES
dc.relation.eventplaceGranadaes_ES
dc.relation.eventdateSeptiembre 2023es_ES
dc.rights.ccAttribution-NonCommercial-NoDerivatives 4.0 Internacional*


Ficheros en el ítem

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Attribution-NonCommercial-NoDerivatives 4.0 Internacional
Excepto si se señala otra cosa, la licencia del ítem se describe como Attribution-NonCommercial-NoDerivatives 4.0 Internacional